Rock Springs Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$120K	Buy	+12,600	New	+$97.8K	0.01%	100
2025 Q2	–	Sell	-222,011	Closed	-$1.67M	–	94
2025 Q1	$1.67M	Sell	222,011 -2,455,985	-92%	-$19.8M	0.1%	81
2024 Q4	$20.1M	Sell	2,677,996 -944,362	-26%	-$7.17M	0.77%	45
2024 Q3	$27.5M	Buy	3,622,358 +3,100	+0.1%	+$23.6K	0.9%	42
2024 Q2	$22.4M	Buy	3,619,258 +123,002	+4%	+$679K	0.68%	49
2024 Q1	$17.8M	Buy	3,496,256 +225,875	+7%	+$1.27M	0.45%	62
2023 Q4	$19.6M	Buy	3,270,381 +719,155	+28%	+$4.17M	0.48%	60
2023 Q3	$18.1M	Buy	2,551,226 +54,033	+2%	+$388K	0.48%	61
2023 Q2	$17.6M	Buy	2,497,193 +163,108	+7%	+$1.31M	0.42%	61
2023 Q1	$19.5M	Buy	2,334,085 +443,348	+23%	+$4.27M	0.46%	56
2022 Q4	$21.7M	Buy	1,890,737 +178,230	+10%	+$2.22M	0.52%	54
2022 Q3	$21.6M	Buy	1,712,507 +251,416	+17%	+$3.24M	0.56%	52
2022 Q2	$15.5M	Buy	+1,461,091	New	+$15.1M	0.45%	60
2019 Q2	–	Sell	-700,000	Closed	-$5.7M	–	136
2019 Q1	$5.7M	Hold	700,000	–	–	0.22%	105
2018 Q4	$5.65M	Hold	700,000	–	–	0.27%	94
2018 Q3	$5.34M	Buy	700,000 +450,000	+180%	+$3.02M	0.19%	116
2018 Q2	$1.43M	Sell	250,000 -675,000	-73%	-$3.72M	0.06%	139
2018 Q1	$4.41M	Buy	925,000 +112,500	+14%	+$578K	0.19%	124
2017 Q4	$3.99M	Buy	812,500 +362,500	+81%	+$1.76M	0.18%	114
2017 Q3	$2.36M	Buy	+450,000	New	+$2.3M	0.11%	128